Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287130 | 0.82 | BCL2 (0.48) | MAPTMEN1KMT2AMAPK1HTT | |
| SCHEMBL1287081 | 0.76 | BCL2 (0.49) | MAPTMEN1KMT2AMAPK1HTT | |
| SCHEMBL10220599 | 0.72 | IDO1 (0.51) | MAPTHPGDMEN1KMT2AMAPK1 | |
| SCHEMBL1287135 | 0.72 | IDO1 (0.59) | MAPTHPGDMEN1KMT2AGAA | |
| SCHEMBL1287142 | 0.71 | RAB9A (0.50) | MAPTMEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL1820826 | 0.70 | DHODH (0.59) | MAPTHPGDMEN1KMT2AMAPK1 | |
| SCHEMBL12158026 | 0.70 | CYP1A2 (0.60) | MAPTHPGDMEN1KMT2AMAPK1 | |
| SCHEMBL7818266 | 0.70 | IDO1 (0.55) | MAPTMEN1KMT2AMAPK1HTT | |
| SCHEMBL12174581 | 0.69 | TP53 (0.59) | MAPTHPGDMEN1KMT2AMAPK1 | |
| SCHEMBL1287124 | 0.68 | MEN1 (0.51) | MAPTHPGDMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040713-B2 | Methods of managing blood sugar levels and compositions related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | claimed |
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-06-20 | — | — | US | claimed |
| WO-2012047628-A2 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-04-12 | — | — | WO | claimed |
| US-9040713-B2 | Methods of managing blood sugar levels and compositions related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012047628-A2 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | SLC5A1, SLC2A1, SLC5A2 | MAPT 2738/4885HPGD 2509/4885MEN1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.